Objective: Endothelial progenitor cells (EPCs) are the key cells of postnatal neovascularization, and mesenchymal stem cells (MSCs) possess pluripotent differentiation capacity and contribute to tissue regeneration and wound healing. Both EPCs and MSCs are critical to the wound repair process, which is hindered in diabetes mellitus. Diabetes has been shown to decrease the function of these progenitor cells, whereas estrogen has beneficial wound healing effects. However, the role of estrogen in modulating EPC and MSC biology in diabetes is unknown. We investigated the effect of estrogen on improving bone marrow (BM)-derived EPC and MSC function using a murine diabetic wound healing model.
The incidence of diabetes mellitus has increased since the 1980s, and in 2012, nearly 30 million Americans had physician-diagnosed diabetes. 1 Complications of diabetes include macrovascular diseases, such as myocardial infarctions, cerebrovascular accidents, and atherosclerosis, as well as microvascular diseases, such as retinopathy, nephropathy, and chronic foot ulcers. Diabetic foot disease affects 15% of all diabetics, with an annual incidence between 1% and 4.1% and an annual amputation rate of 0.21% to 1.37%, [2] [3] [4] making it the leading cause of nontraumatic lower extremity amputations. 5 Patients who have undergone lower extremity amputations have a 5-year mortality rate of 50% to 60%, 6, 7 mostly attributed to the increased work of ambulating with a prosthetic limb and the resulting myocardial strain in these patients. 7, 8 Studies have shown that elderly male patients have the highest incidence of chronic nonhealing wounds, correlating with reduced levels of estrogen 9, 10 and maintenance of the androgen hormones that are detrimental to healing. 11, 12 In addition, topical estrogen has been shown to be beneficial in accelerating cutaneous wound healing in both sexes. [12] [13] [14] For example, 17b-estradiol enhances the ability of endothelial cells to form capillary-like structures. [15] [16] [17] Furthermore, estrogen stimulates the expression by monocytes and macrophages of platelet-derived growth factor, which is chemotactic for dermal fibroblasts and promotes fibroblast-driven wound contraction. [17] [18] [19] Estrogen also increases secretion of transforming growth factor b1 by dermal fibroblasts, 13 which subsequently induces the formation of granulation tissue and promotes collagen deposition. 17, 20, 21 Studies have shown that bone marrow (BM)-derived stem/progenitor cells, including endothelial progenitor cells (EPCs) and mesenchymal stem cells (MSCs), have pivotal roles in wound healing in the context of neovascularization, fibroblast differentiation, collagen deposition, and tissue regeneration. EPCs are well-established sources of endothelial cells that participate in both reparative and pathologic postnatal neovascularization and contribute to tissue repair in limb ischemia, [22] [23] [24] post-myocardial infarction repair, 25 MSCs primarily reside in their respective niches in the BM, and when stimulated by specific signals, they are released into the circulation and recruited to specific tissues to undergo in situ differentiation and production of soluble factors contributing to tissue regeneration. [37] [38] [39] EPCs and MSCs are critical in the healing of acute and chronic wounds as they contribute to neovascularization and fibroblast-collagen deposition, respectively. With the knowledge that estrogen increases these processes in the chronic wound, we hypothesize that an additional action of estrogen in wound healing may be to modulate stem/progenitor cells in the diabetic setting. Estrogen has been shown to increase MSC proliferation 40, 41 and differentiation. 42 In this study, we demonstrate that the in vitro viability and proliferation of EPCs and MSCs in diabetic mice in the presence of topical estrogen treatment are increased as measured by the colony-forming units (CFUs). Correspondingly, increased local recruitment of EPCs and collagen deposition are found in estrogentreated vs placebo-treated diabetic wounds. Therefore, topical estrogen treatment promotes wound neovascularization and healing. Our study reveals a novel mechanism of topical estrogen treatment in the improvement of diabetic wound healing through modulating BM-derived stem/progenitor cells.
METHODS
Mice and generation of peripheral cutaneous wounds. All procedures were done with approval from the University of Miami Institutional Animal Care and Use Committee. Diabetic female mice (db þ /db þ ) and nondiabetic control mice (db þ /db À ) at 10 weeks of age were purchased from Jackson Laboratory (Bar Harbor, Me). All experiments were carried out at 17 weeks of age, and before all surgical procedures, serum glucose concentration was measured from the mouse tail vein by a glucometer. Mean serum glucose levels in diabetic mice were 402.5 mg/dL (range, 287-505 mg/dL). For all surgical procedures, mice were anesthetized with an intraperitoneal injection of 0.15 mL of a concoction consisting of 100 mg/kg of ketamine and 10 mg/kg of xylazine. Two wounds were induced on the dorsal surface of each mouse with an 8-mm punch biopsy. Fullthickness skin was removed, exposing the underlying muscle. Each wound was subsequently treated with EstroGel 0.06% cream or EstroGel placebo cream (ASCEND Therapeutics, Herndon, Va) for 5 days after wounding.
Assessment of wound closure rate. Wounds were observed serially with daily digital photographs using an Olympus digital camera (Olympus, Tokyo, Japan). A ruler was included in all photographs to allow calibration of measurements. Images were analyzed using ImageJ software (Imaging Processing and Analysis in Java, National Institutes of Health, Md). Wound area was measured each day, and the wound's percentage recovery rate was expressed as (original wound area minus daily wound area) / (original wound area) Â 100. Whereas half of the mice (n ¼ 6) were sacrificed on day 5, the other half were followed out to day 15 or full wound closure, whichever came first. 
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BM isolation and CFUs. On day 5 after wounding, three mice from each group were sacrificed, and bilateral femur and tibia were removed. BM was subsequently isolated by flushing 2% Iscove modified Dulbecco medium (Invitrogen, Carlsbad, Calif) through a 27-gauge needle. The resulting suspension was strained to remove bone fragments and adipose tissue. The cell suspension was washed in phosphate-buffered saline twice, and 10 6 cells were plated per well on six-well culture dishes coated with 5 mg/mL of fibronectin in complete EGM2 medium containing supplements and 5% fetal bovine serum (FBS; Cambrex Bioscience, Walkersville, Md) for EPC culture. In addition, 10 6 cells were plated per well on uncoated six-well culture dishes in Dulbecco modified Eagle medium (Invitrogen) supplemented with 10% FBS for MSC culture. All cells were incubated at 37 C in 98%
humidified air containing 5% CO 2 . The medium was changed on day 5 after plating, and CFUs were counted under a microscope on day 10 after plating.
Fluorescence-activated cell sorting. A portion of the fresh BM isolated on day 5 after wounding was subjected to fluorescence-activated cell sorting analysis for number of EPCs. After isolation from BM and washing with both phosphate-buffered saline and Hank's buffer (with 2% FBS), 10 6 BM cells were incubated with fluorescein isothiocyanate (FITC)-anti-CD31 and phycoerythrin-anti-CD34 (BD Biosciences, San Jose, Calif) for an hour. Nonimmunogenic, isotype-matched antibodies were used as controls. After incubation, all cells were washed in Hank's buffer twice and analyzed by flow cytometry, and the percentage of double-positive cells was analyzed.
Live animal blood vessel perfusion and laser scanning confocal microscopy. On day 15, the remaining three mice were anesthetized, and blood vessels were directly labeled in vivo by live perfusion using a formatted aqueous solution (7 mL/mouse) containing DiI (D-282; Invitrogen/Molecular Probes), which is incorporated into endothelial cell membranes on contact and was administered through direct intracardiac injection before animal sacrifice as previously described. 43 After
DiI perfusion, 7 mL of fixative (4% paraformaldehyde) was injected, and the entire wound tissue was harvested. 
/db
À mice (*; P ¼ .001), which was also partially rescued by topical estrogen treatment (**; P ¼ .03). Data are presented as mean 6 standard deviation of three replicates. N ¼ 6 mice/group. 6000 microscope with motorized stage [Leica Technology, Exton, Pa]). Vessel density was quantified by assessing total number of red DiI-labeled vessels normalized to the entire scanned wound area, using MetaMorph 5.07 (Universal Imaging/Molecular Devices, Downingtown, Pa). Scar density was quantified by assessing total number of black pixels to the entire scanned wound area, using the same software.
Immunostaining. For immunostaining, 5-mm paraffin sections from each perfused mouse (N ¼ 6; vessels labeled with DiI) were processed in triplicate as described 41 and
were then incubated with anti-CD34 (Cell Signaling Technology, Danvers, Mass) overnight at 4 C, followed by incubation with FITC-conjugated secondary antibodies.
Immunoreactivity was detected using a fluorescent microscope. For negative controls, primary antibodies were replaced with nonimmunogenic, isotype-matched antibodies from the same manufacturer. Double-positive vessels were quantified by randomly selecting six fields per condition and tallying the number of vessels with incorporated EPCs.
Statistical analysis. We performed a two-tailed Student t-test based on six mice/group that provided 85% power for statistical differences. This was based on our data from previous studies in which the standard deviations of the change of blood vessel density in wounds were #0.05. Data were analyzed using Microsoft Excel (Microsoft Corp, Redmond, Wash). Data are expressed as mean 6 standard deviation. Values are considered statistically significant when P < .05.
RESULTS
Systemic absorption of topical estrogen treatment was ascertained by weighing the uterus of diabetic db þ /db þ mice with and without treatment. Mean uterine weight in estrogen-treated mice was 0.136 mg (range, 0.08-0.178 mg), whereas mean uterine weight in placebo-treated mice was 0.021 mg (range, 0.018-0.024 mg; P ¼ .016). Estrogen treatment did not alter the number of BM-EPCs in diabetic mice (11.56% EPCs in the placebo-treated group vs 10.26% EPCs in the estrogen-treated group; Fig 1) . Because partial rescue was observed, we continued our experiments using only the diabetic (db þ /db þ ) mice. We examined whether topical application of estrogen affected the recruitment of EPCs in the cutaneous wound tissue. In the mice that underwent live perfusion with DiI, the wounds were harvested and subjected to immunostaining. Blood vessels were stained with red fluorescence due to DiI labeling, and EPCs recruited to wound tissues and incorporated into blood vessels were detected by FITC-anti-CD34. The combination of the two colors (red and green converted to yellow) represents recruited BM-derived EPCs. Compared with diabetic wounds treated with placebo cream, wounds treated with estrogen cream had significantly more BM-derived EPCs (Fig 3, a) . Five randomly selected high-power fields (magnification Â40) were tallied for each treatment group, and it was found that 75% of newly formed vessels in the estrogen-treated group had incorporated EPCs compared with 27% of those in the placebo-treated group (P ¼ .04 ; Fig 3, b) . This is consistent with less active neovascularization in the placebo-treated mice (Fig 4) . These in vivo experiments demonstrated that topical application of estrogen increases recruitment of BM-derived EPCs to the diabetic wound tissues.
The effect of topical estrogen on the neovascularization of the cutaneous wound bed was evaluated by blood vessel DiI-acetylated low-density lipoprotein perfusion and subsequent laser scanning confocal microscopy on day 15 after wounding. In comparison to wounds in diabetic db þ /db þ mice with placebo treatment, wounds of diabetic db þ /db þ mice with estrogen treatment had more active neovascularization in the wound bed as well as in the area immediately surrounding the wound (Fig 4, a) . After assessment of the degree of neovascularization of the entire wound, four randomly selected fields in each group were used to quantify vessel density using MetaMorph 5.07. Diabetic db þ /db þ mice wounds treated with estrogen cream had significantly higher vessel density than diabetic db þ /db þ wounds treated with placebo cream (1.51% vs 0.21%; P ¼ .003; Fig 4, b) , suggesting that topical estrogen treatment increased neovascularization of cutaneous wounds in diabetic mice. To follow the progress of skin wound healing, daily wound area measurements were obtained by digital photography (Fig 5, a) , and the wound area was calculated using ImageJ software. A significant wound healing advantage was observed for estrogen-treated diabetic wounds starting as early as day 6, which continued through day 13 (P ¼ .036 on day 6, .023 on day 7, .005 on day 9, .022 on day 11, and .067 on day 13; Fig 5, b) . These results suggest that topical estrogen treatment improves and accelerates wound healing in diabetic mice.
To study the relation of scar density with collagen deposition, collagen deposition in the granulation tissue was determined by measuring the density of scar formed using confocal microscopy in harvested wound tissue at day 15. The red phase, which A proangiogenic effect of estrogen treatment on diabetic wound neovascularization. In comparison to diabetic wounds treated with placebo, estrogen-treated wounds had denser neovascularization in the wound bed and the area immediately surrounding the wound. a, Representative confocal laser microscopy images. b, Quantitation of vessel density from four randomly selected fields (magnification Â40) in each group (*; P ¼ .003). N ¼ 6 mice/group. constitutes blood vessels, was removed from the images, leaving equal thickness of granulation tissue, with darker areas representing scar that indicates the levels of collagen deposition (Fig 6, a) . Diabetic wounds that underwent estrogen treatment had high levels of collagen deposition (71.2% vs 0.83%; P ¼ .04; Fig 6, b) . Consequently, topical estrogen treatment increases collagen deposition in the granulation tissue of cutaneous wounds.
DISCUSSION
Age-related wound healing studies suggest that sex steroid hormones may have a substantial influence on the healing response: estrogen accelerates wound healing, whereas androgens hinder the process. 17 The effect of estrogen is multimodal as it influences cutaneous wound healing by modulation of inflammation and cytokine expression, 11 matrix deposition, 44 keratinocyte proliferation and apoptosis, 45 ,46 acceleration of re-epithelialization, 13 ,44 Wound blood vessel perfusion with DiI dye. a, Representative images of DiI-stained wound blood vessels measured by laser scanning confocal microscopy at day 15 are shown for each group. b, Quantification of vessel density in the wounds. Percentage of threshold area covers all vessels detected as a percentage of the entire wound area (*; P ¼ .036 on day 6, .023 on day 7, .005 on day 9, .022 on day 11, and .067 on day 13). N ¼ 6 mice/group. and stimulation of angiogenesis and wound contraction. 17 Estrogen deprivation in ovariectomized female mice results in markedly impaired wound healing and enhanced inflammation, delayed re-epithelialization, and decreased collagen deposition. 13, 14, 17 Topical and systemic estrogen treatments have been shown to increase the rate of acute healing in men and elderly women.
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Our study now adds a novel mechanism underlying the proangiogenic and prohealing effect of estrogen in the treatment of diabetic wounds. EPCs and MSCs are reserved in their respective microenvironments, or niche, in the BM and can be mobilized into circulation in response to trauma or ischemia. 47 After mobilization, they home to specific sites where neovascularization and tissue regeneration are needed by chemokines and growth factors, undergo in situ differentiation, and produce soluble factors to participate in the regulation of new vessels and ECM deposition. 48 This process is complex and well regulated.
Diabetes mellitus contributes to reduction and dysfunction of circulating EPCs. 49, 50 EPCs isolated from diabetic patients have decreased proliferation and adherence to endothelial cells and reduced ability to participate in tubule formation. 50 Ischemia-induced increase in circulating EPCs does not occur in diabetes. [49] [50] [51] [52] Interestingly, this is not attributable to decreased numbers of progenitor cells in the BM niche; rather, it is attributable to dysfunctional release of these cells. 53 The decreased number of circulating EPCs in diabetes has two probable causes: impaired mobilization and consumptive loss of EPCs due to increased endothelial damage in diabetes. 54 Our experiments demonstrate that topical estrogen has stimulatory effects on BM-derived EPCs and MSCs in the setting of diabetes. Although the number of BM-EPCs is unchanged in the BM after topical estrogen treatment on the wound, their in vitro viability and proliferation are significantly increased. Importantly, we found that topically treated cutaneous wounds have a significantly higher degree of neovascularization as well as EPC-incorporated microvasculature, as reflected by immunostaining. Similar to EPCs, the in vitro viability of MSCs is also increased on topical estrogen treatment, and collagen deposition in the granulation tissue is significantly higher in cutaneous wounds treated with topical estrogen. Previous studies have shown that topical 17b-estradiol treatment of diabetic wounds improves and accelerates wound healing by decreasing matrix metalloproteinase activity (matrix metalloproteinases 2, 13, and 14) and increasing collagen content. 55 It has been reported that an estrogen receptor b agonist can normalize fasting glucose levels to enhance endogenous insulin secretion and to improve glucose homeostasis in several models of diabetes including db/db mice. 56 In combination, all of these critical events in wound healing may contribute to improved healing of cutaneous wounds in diabetic mice treated with topical estrogen. Our study represents the first to date documenting that topical estrogen treatment increases the viability of BM-derived EPCs and MSCs. It suggests that more viable EPCs and MSCs may contribute to increased wound neovascularization, faster cutaneous wound healing, and improved scar formation. This new knowledge is in accordance with the revolutionary new findings from the last 10 years regarding the role of sex hormones in wound healing. Our study was based on a limited sample size (N ¼ 6 mice/group); therefore, the results are preliminary and need to be validated by future studies. Taking into consideration the importance of EPCs and MSCs in tissue regeneration and wound healing, future studies should be undertaken to study the mechanism of estrogen in modulating these critical cells. In addition, although it is certain that an imbalance of circulating sex steroids is not the only causative factor of the impaired dermal repair that occurs in the elderly diabetic patient, it represents a potential target for therapeutic intervention that warrants further investigation. 
CONCLUSIONS
Our findings reveal that topical estrogen treatment significantly increases the viability of BM-derived EPCs and MSCs, supporting their actions on cutaneous wound healing: neovascularization and granulation tissue deposition, respectively. Therefore, topical estrogen therapy may be an effective strategy for the treatment of cutaneous wounds by modulating BM-derived stem/progenitor cells.
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